Immunoprophylaxis for respiratory syncytial virus.
Sánchez
Pablo J
PJ
Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D017281:Cost of Illness; D006760:Hospitalization; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000517:prevention & control*; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D000069455:Palivizumab